Overview

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of BGG492 as adjunctive treatment in patients with refractory partial onset seizures
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Anticonvulsants